C5
Reaktivität: Human
WB, IA
Wirt: Maus
Monoclonal
557
unconjugated
Applikationshinweise
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
0.1 mg/mL
Buffer
PBS, 0.02 % sodium azide, 0.1 % bovine serum albumin
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C
Informationen zur Lagerung
Store at 2 - 8 °C.
Target
C5
(Complement Component 5 (C5))
Andere Bezeichnung
Complement C5
Hintergrund
C5 is involved in the activation of the lythic pathway within the complement system which is an important factor in innate immunity. The complement pathways can be divided in the activation pathways and lytic pathway. The activation pathways lead via C3 to the cleavage of the fifth complement component C5 into C5a and C5b. C5a induces smooth muscle contraction, increases vascular permeability, causes degranulation of mast cells and basophils, and release of lysosomal enzymes. In addition C5a stimulates the directed migration of neutrophils, eosinophils, basophils and monocytes. Studies indicate the modulation of the acute-phase response in liver and an overall immune response by inducing synthesis of cytokines such as TNF-alpha, IL-1beta, IL-6 and IL-8. C5b initiates the assembly of the membrane attack complex (MAC) that mediates cytolysis.Synonyms: C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, CPAMD4, Complement component 5